Gov’t hit over preference for Sinovac’s ‘pasang-awa’ vaccine
MANILA, Philippines (Updated 3:09 p.m.) — Some opposition lawmakers are questioning the government’s continued preference for Sinovac Biotech’s coronavirus vaccine, even after late-stage clinical trials in Brazil showed that its efficacy rate only stands at 50%.
The World Health Organization set a minimum efficacy rate of 50% for vaccines to be used, but its preferred efficacy rate is at least 70%.
Senate Majority Leader Migz Zubiri said Friday it is "totally unacceptable" and a "total waste of our funds and resources" for the government to be procuring a vaccine with only a 50% efficacy rate.
“Why settle for this 'pasang-awa' kind of vaccine when we can get more efficient ones at a lower price?” Rep. Ferdinand Gaite (Bayan Muna party-list) said Friday.
Senate finance committee chair Sonny Angara previously presented prices of seven coronavirus vaccines during a Senate hearing, which showed that Sinovac’s inoculation is the second-most expensive shot at P3,629.50 for two doses following Moderna Biotech’s jab which costs up to P4,504 for two doses.
American drugmaker Pfizer and German biotechnology company BioNTech’s coronavirus vaccine is the third most expensive, coming at P2,379 for two doses.
Pfizer/BioNTech and Moderna’s inoculations, which have been approved for emergency use in the United States, boast efficacy rates above 90%, while the efficacy rate of Sinovac’s vaccine is still shrouded with doubts as experts point out a lack of transparency in the release of data on the shot.
“The Duterte administration’s continued preference for China-made Sinovac COVID-19 vaccines must be thoroughly questioned,” Rep. Arlene Brosas (Gabriela party-list) said. “Why does it seem that China has given Christmas gifts which is why the government is bent on this expensive yet only half-as-effective vaccine?”
“We hope that 'kickvac' allegations are not true and we must see the whole COVID-19 vaccination plan of the [Inter-Agency Task Force on the Management of Emerging Infectious Diseases],” Gaite said.
‘Tolerating mediocrity’
Tony Leachon, a former adviser to the task force that implements the country’s policies on COVID-19, hit the government for “tolerating mediocrity” in preferring Sinovac’s jab.
“If Pfizer and Moderna boast of 95% efficacy rate and AstraZeneca has 70%, why would Philippines settle for Sinovac 50% efficacy rate and much more expensive than Pfizer and Astra[Zeneca]?” Leachon said.
“If other countries would like to have world class vaccines with 95% efficacy rate, why can't we? If we allow it, then we set up ourselves to have mediocre immune response,” he added.
The Philippine Council for Health Research and Development, an agency under the Department of Science and Technology tasked to evaluate coronavirus vaccine candidates, said Thursday that Sinovac’s shot may be deemed “acceptable,” but stressed that the Philippines needs to review full data on its efficacy before it can be used in the country.
Presidential spokesperson Harry Roque had defended the government’s keenness on the Sinovac vaccine, saying that the biopharmaceutical company is the only manufacturer who could supply the country with inoculations at the soonest possible time.
24M eyed to get shot
The Philippines is eyeing to buy 25 million doses of Sinovac’s coronavirus vaccine, which is still undergoing late-stage trials.
Unlike its Southeast Asian neighbors Singapore and Indonesia which secured several vaccine supply deals with various manufacturers, the Philippines has only signed one agreement with one supplier, British-Swedish drugmaker AstraZeneca, for 2.6 million doses which was made possible by some 30 private firms who pitched in to buy the shots.
The government eyes to ink a second deal with AstraZeneca for 30 million more doses of its inoculation by next week once it is approved for emergency use by the United Kingdom’s Ministry of Health Regulatory Authority.
The country is also eyeing to secure four to 25 million doses of vaccines from Moderna and Arcturus, while vaccine czar Carlito Galvez said that American vaccine developer Novavax has committed to providing the country 30 million doses of its coronavirus shot.
The country, which has the second-worst coronavirus outbreak in the Southeast Asian region following Indonesia, is targeting to vaccinate 24 million people against the virus that causes COVID-19 by next year.
Pharma giants Sanofi and GSK said on July 29, 2020, that they have agreed to supply Britain with up to 60 million doses of a potential COVID-19 vaccine. The agreement covers a vaccine candidate developed by France's Sanofi in partnership with the UK's GSK and is subject to a "final contract."
This thread collects some of the major developments in the search for a vaccine to ease the new coronavirus pandemic. (Main photo by AFP/Joel Saget)
As negotiations towards a new pandemic treaty pick up pace, observers warn of watered-down efforts to ensure equitable access to the medical products needed to battle future Covid-like threats.
Shaken by the pandemic, the World Health Organization's 194 member states are negotiating an international accord aimed at ensuring countries are better equipped to deal with the next catastrophe, or even prevent it altogether.
The process is still in the early stages, with the aim of reaching an agreement by May 2024.
But critics warn that revisions being made to the preliminary negotiating text are weakening the language -- notably in a key area aimed at preventing the rampant inequity seen in access to vaccines and other medical products during the Covid pandemic.
"I think it is a real step backwards," Suerie Moon, co-director of the Global Health Centre at the Geneva Graduate Institute, told AFP. — AFP
Africa's first mRNA vaccine hub is ceremonially launched on Thursday to acclaim from the UN's global health chief, who hailed it as a historic shift to help poor countries gain access to life-saving jabs.
The facility was set up in the South African city of Cape Town in 2021 on the back of the success of revolutionary anti-Covid vaccines introduced by Pfizer/BioNTech and Moderna.
"This precious project... will bring a paradigm shift in addressing the serious problem we faced, the equity problem, during the pandemic, so (that) it's not repeated again," World Health Organization (WHO) head Tedros Adhanom Ghebreyesus tells a media briefing to mark the inauguration. — AFP
China has approved its first locally developed messenger RNA (mRNA) vaccine against Covid-19, its manufacturer said Wednesday, months after the relaxation of strict Covid-zero regulations sparked a surge in cases.
The vaccine, developed by CSPC Pharmaceutical Group Ltd, has been approved for "emergency use" by Beijing's health regulator, the company said in a statement.
It showed high efficacy in a trial in which it was used as a booster shot for people who have been given other types of vaccines, the company added, without offering further details. — AFP
COVID-19 vaccine maker Novavax raises doubts about its ability to continue its business, announcing plans to cut spending after struggles in rolling out its coronavirus jab.
Shares of Novavax plummeted 25 percent in extended trading, after the company reported fourth-quarter earnings that missed analyst estimates.
While the firm should have enough money to fund operations, the situation is "subject to significant uncertainty," it says in a statement. — AFP
The protection against Covid-19 from being previously infected lasts at least as long as that offered by vaccination, one of the largest studies conducted on the subject says.
Ten months after getting Covid, people still had an 88% lower risk of reinfection, hospitalisation and death, according to the study published in the Lancet journal.
That makes this natural immunity "at least as durable, if not more so" than two doses of Pfizer or Moderna's vaccines, the study says.
The authors nevertheless emphasized that their findings should not discourage vaccination, which remains the safest way to get immunity. — AFP
- Latest
- Trending
